299 related articles for article (PubMed ID: 2083515)
41. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
Farmer JA; Washington LC; Jones PH; Shapiro DR; Gotto AM; Mantell G
Clin Ther; 1992; 14(5):708-17. PubMed ID: 1468089
[TBL] [Abstract][Full Text] [Related]
42. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.
Kostner GM; Gavish D; Leopold B; Bolzano K; Weintraub MS; Breslow JL
Circulation; 1989 Nov; 80(5):1313-9. PubMed ID: 2530005
[TBL] [Abstract][Full Text] [Related]
43. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
Lintott CJ; Scott RS; Sharpe DN; Nye ER; Charleson H; French JK; White HD; Reuben S; Maling TJ; Lewis GR
Med J Aust; 1991 Oct; 155(7):433-6. PubMed ID: 1921811
[TBL] [Abstract][Full Text] [Related]
44. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
Riesen WF; Keller U; Del Bufalo A; Reutter FW; Baur HR; Golay A; Bertel O; Kummer H; Kistler H; Ammann F
Schweiz Med Wochenschr; 1989 Dec; 119(48):1719-23. PubMed ID: 2694363
[TBL] [Abstract][Full Text] [Related]
45. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
46. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
Hoeg JM; Brewer HB
JAMA; 1987 Dec; 258(24):3532-6. PubMed ID: 3316727
[TBL] [Abstract][Full Text] [Related]
47. [Maximal treatment of hypercholesteremia: what is possible?].
Thiery J
Arzneimittelforschung; 1990 Mar; 40(3A):383-8. PubMed ID: 2185771
[TBL] [Abstract][Full Text] [Related]
48. [Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin].
Mantell G
Therapie; 1992; 47(2):161-4. PubMed ID: 1412144
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
[TBL] [Abstract][Full Text] [Related]
50. Benefits and risks of simvastatin in patients with familial hypercholesterolaemia.
Mata P; Alonso R; Badimón J
Drug Saf; 2003; 26(11):769-86. PubMed ID: 12908847
[TBL] [Abstract][Full Text] [Related]
51. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia.
Hagemenas FC; Pappu AS; Illingworth DR
Eur J Clin Invest; 1990 Apr; 20(2):150-7. PubMed ID: 2112479
[TBL] [Abstract][Full Text] [Related]
52. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
Saxenhofer H; Weidmann P
Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
[TBL] [Abstract][Full Text] [Related]
53. Simvastatin increases plasma NO2- and NO3- levels in patients with hypercholesterolemia.
Nakashima Y; Toyokawa Y; Tanaka S; Yamashita K; Yashiro A; Tasaki H; Kuroiwa A
Atherosclerosis; 1996 Nov; 127(1):43-7. PubMed ID: 9006803
[TBL] [Abstract][Full Text] [Related]
54. [Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia].
Aubert I; Emmerich J; Charpak Y; Chanu B; Dachet C; Herlich D; Besseau M; Rouffy J; Jacotot B
Presse Med; 1988 May; 17(18):901-4. PubMed ID: 2968595
[TBL] [Abstract][Full Text] [Related]
55. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
56. [The effects of the cholesterol synthesis inhibitor simvastatin in patients with hypercholesterolemia with and without diabetes mellitus].
van Deursen RT; Nieuwenhuijzen Kruseman AC; Degenaar CP; Wolffenbuttel BH
Ned Tijdschr Geneeskd; 1990 Nov; 134(44):2142-6. PubMed ID: 2247172
[TBL] [Abstract][Full Text] [Related]
57. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors.
Sehayek E; Butbul E; Avner R; Levkovitz H; Eisenberg S
Eur J Clin Invest; 1994 Mar; 24(3):173-8. PubMed ID: 8033951
[TBL] [Abstract][Full Text] [Related]
58. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.
Slunga L; Johnson O; Dahlén GH
Eur J Clin Pharmacol; 1992; 43(4):369-73. PubMed ID: 1451715
[TBL] [Abstract][Full Text] [Related]
59. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
[TBL] [Abstract][Full Text] [Related]
60. A one-year multicentre study of simvastatin in the treatment of hypercholesterolaemia. UK and Eire Simvastatin Study Group.
Br J Clin Pract; 1994; 48(5):231-5. PubMed ID: 7917813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
